Angiotensin-(1-7): Non-Toxic, Targeted Cancer Therapeutic

Although toxic chemotherapies effectively treat many types of cancer, these therapies contribute to poor quality of life and, in many cases, cause detrimental side effects.

Treating patients with Angiotensin-(1-7), which inhibits cancer cell growth with little or no toxicity or side effects, is a safe and effective alternative to conventional cytotoxic medicines.

Invention Summary

Angiotensin-(1-7) inhibits cancer cell growth with little or no toxicity or side effects. This drug acts against cancer in two distinct ways – by directly inhibiting cell growth and by restricting the blood supply to tumors through reduced blood vessel formation – without the unwanted toxicity of traditional chemotherapeutics.

Ang-(1-7) has proven anti-cancer effects in preclinical models of breast, prostate, and lung cancers and sarcomas, validating its potential for use in a wide range of clinical settings. This drug has been clinical Phase 1 and Phase 2 studies which demonstrate that it is well-tolerated and that it may be an effective therapy for certain cancers and sarcomas.

Competitive Benefits

  • Ang-(1-7) specifically targets proliferating cancer cells, thus minimizing side effects attributed to undesired targeting of healthy cells.
  • It possesses anti-cancer effects in many cancer types, including cancers of the lung, breast, prostate and sarcomas.
  • It does not produce alterations in blood pressure, heart rate or wound healing when used for the treatment of cancer in the clinic at therapeutic doses.
  • Ang-(1-7) and its analogs appear to act at the MAS oncogenic receptor in a novel mechanism with demonstrated translational validation.

Application Fields

  • Treatment of sarcomas and lung, breast, prostate and connective tissue cancers.
  • May also be used to treat non-solid tumors

Status

  • A successful Phase 2 clinical trial of Ang-(1-7) for second or third line treatment of patients with metastatic or unresectable sarcomas is complete.
  • Phase 1 clinical trials have been completed for the study of Ang-(1-7) in the treatment of solid tumors in human patients.
  • Ang-(1-7) has demonstrated effective inhibition of cancer cell growth in vitro and tumor growth in mouse models.
  • Assessment of the molecular mechanisms targeted by Ang-(1-7) to mediate its anti-cancer effects are underway.
  • Inventors are developing next-generation Ang-(1-7) products and formulations, including new lead compounds with pharmacological and pharmacokinetic profiles superior to Ang-(1-7) in preclinical models.
  • Information on these new analogs and findings will be provided under confidentiality agreements.

Inventors

  • E. Ann Tallant, PhD.
  • Patricia E. Gallagher, PhD.
  • Carlos M. Ferrario, MD.

Patents

US Patent No. 8,034,781; US Patent No. 7,122,523; and US Patent No. 7,375,073

Related Publications

Phase 1 and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone. Clin Cancer Res. 2009 Dec 1;15 (23):7398-404.

Licensing Contact

Michael Batalia, PhD, CLC
Executive Director, Commercialization
+1.336.716.3729
mbatalia@wakehealth.edu

Back to Top